LENSAR (NASDAQ:LNSR) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of LENSAR (NASDAQ:LNSR) from a sell rating to a hold rating in a research report sent to investors on Saturday.

A number of other equities analysts have also recently commented on the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of LENSAR in a report on Friday, August 7th. Lake Street Capital reissued a “buy” rating and set a $13.00 price target on shares of LENSAR in a report on Thursday. Finally, BTIG Research upped their price target on LENSAR from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $11.00.

LENSAR Trading Down 0.8%

Shares of LNSR stock opened at $8.20 on Friday. LENSAR has a 12 month low of $4.95 and a 12 month high of $12.96. The stock has a market cap of $100.70 million, a P/E ratio of -24.85 and a beta of 0.89. The company has a 50 day simple moving average of $5.89 and a two-hundred day simple moving average of $7.37.

LENSAR (NASDAQ:LNSR) last issued its quarterly earnings results on Thursday, August 13th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.26. The business had revenue of $16.50 million for the quarter, compared to analysts’ expectations of $14.65 million. LENSAR had a net margin of 57.57% and a negative return on equity of 253.03%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of LENSAR in the second quarter valued at about $1,057,000. DCF Advisers LLC bought a new position in shares of LENSAR during the 2nd quarter valued at about $675,000. Geode Capital Management LLC boosted its holdings in shares of LENSAR by 103.9% during the 2nd quarter. Geode Capital Management LLC now owns 219,373 shares of the company’s stock valued at $2,890,000 after purchasing an additional 111,802 shares during the last quarter. Brandes Investment Partners LP grew its position in shares of LENSAR by 10.1% during the fourth quarter. Brandes Investment Partners LP now owns 856,216 shares of the company’s stock valued at $9,958,000 after purchasing an additional 78,513 shares in the last quarter. Finally, Man Group plc purchased a new position in shares of LENSAR during the second quarter valued at about $445,000. Institutional investors own 40.15% of the company’s stock.

LENSAR News Roundup

Here are the key news stories impacting LENSAR this week:

• Positive Sentiment: LENSAR reported second-quarter revenue of $16.5 million, above analysts’ $14.65 million consensus estimate, and earnings of $0.10 per share versus expectations for a $0.16 loss. The results point to a significant improvement in profitability and operating performance. LENSAR Reports Second Quarter 2026 Results and Provides Business Update
• Positive Sentiment: The company placed 10 ALLY Robotic Cataract Laser Systems during the quarter, increasing its installed base to 445 systems. The ALLY backlog stood at 13 systems at June 30, suggesting continued near-term demand and potential future revenue. LENSAR signals opex to rise modestly as ALLY backlog reaches 13 systems
• Positive Sentiment: Recurring revenue reached $13.7 million, while ALLY placements grew 30%. The recurring-revenue base could improve visibility and support more consistent results as the installed system base expands. LENSAR Q2 2026 Earnings Call Highlights
• Positive Sentiment: BTIG Research raised its LENSAR price target from $7 to $9 and assigned a Buy rating, reflecting greater confidence following the earnings beat and business update.
• Neutral Sentiment: Management indicated that operating expenses will increase modestly, likely reflecting investments needed to support commercialization and the growing ALLY system base. This could temper the pace of future margin expansion.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.